25 unknown. 25 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Unknown 25 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Hodgkin Lymphoma: new trials by email Literature Review of Hodgkin Lymphoma trials Research Report on Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma Prolgolimab, Combination with prolgolimab and bendamustine - Hodgkin Lymphoma | Phase 2 | Unknown | St. Petersburg State Pavlov Medical University | 30 | 2023-04-19 | 2023-12-19 |
| BV-AVD-R Treatment Children Hodgkin's Lymphoma Brentuximab vedotin, Rituximab, Doxorubicin - Hodgkin Lymphoma | Phase 2 | Unknown | Beijing Children's Hospital | 44 | 2022-10-01 | 2024-01-12 |
| A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT Tislelizumab - Hodgkin Lymphoma, Chemotherapy Effect | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2021-05-01 | 2021-04-13 |
| Radiation Free Chemotherapy for Early Hodgkin Lymphoma Nivolumab 10 MG/ML - Hodgkin Lymphoma | Phase 2 | Unknown | Medical University of Gdansk | 160 | 2021-03-04 | 2021-08-12 |
| The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab - Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | Phase 2 | Unknown | Chinese PLA General Hospital | 200 | 2020-08-01 | 2020-08-18 |
| Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma Chidamide, Camrelizumab, Decitabine - Hodgkin Lymphoma | Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2020-02-02 | 2020-08-14 |
| Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma Camrelizumab(SHR-1210) - Hodgkin Lymphoma | Phase 2 | Unknown | Peking University | 84 | 2020-01-01 | 2020-01-23 |
| Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study Avelumab - Hodgkin Lymphoma | Phase 2 | Unknown | University College, London | 49 | 2019-09-27 | 2023-12-12 |
| Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Camrelizumab and Decitabine - Hodgkin Lymphoma | Phase 2 / Phase 3 | Unknown | Chinese PLA General Hospital | 100 | 2019-09-01 | 2020-08-12 |
| Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma Nivolumab - Hodgkin Lymphoma | Phase 2 | Unknown | National Research Center for Hematology, Russia | 50 | 2019-08-19 | 2022-12-21 |
| Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen MOAP - Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Han weidong | 30 | 2019-07-30 | 2019-07-19 |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma Chidamide, Cladribine, gemcitabine - Hodgkin Lymphoma, Non-hodgkin Lymphoma | Phase 2 | Unknown | Sichuan University | 30 | 2019-01-01 | 2018-07-26 |
| ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma Nivolumab - Hodgkin Lymphoma | Phase 2 | Unknown | University College, London | 78 | 2018-12-03 | 2024-05-10 |
| A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma pembrolizumab - Hodgkin Lymphoma | Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 27 | 2018-11-29 | 2023-08-21 |
| BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) BrentuximabVedotin (BV) - Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 41 | 2018-08-08 | 2024-02-26 |
| BV After Allogeneic Hematopoietic Stem Cell Transplantation Brentuximab Vedotin (Bv) - Hodgkin Lymphoma | Phase 2 | Unknown | University Hospital, Caen | 58 | 2018-03-07 | 2018-05-30 |
| OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy Adriamycin, Cyclophosphamide, Vinblastine - Classical Hodgkin Lymphoma, Hodgkin Lymphoma (Category) | Phase 2 | Unknown | King Abdullah International Medical Research Center | 220 | 2018-01-01 | 2019-11-18 |
| SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma SHR-1210, Decitabine - Hodgkin Lymphoma | Phase 2 | Unknown | Chinese PLA General Hospital | 280 | 2017-09-11 | 2019-04-01 |
| Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Thiotepa - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 2 | Unknown | Sheba Medical Center | 24 | 2015-09-01 | 2016-04-20 |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning - Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | New York Medical College | 20 | 2014-03-01 | 2022-10-27 |
Showing 20 of 25. Sign in to see all of them.
Hodgkin Disease (25) · Lymphoma, Non-Hodgkin (3) · Recurrence (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Multiple Myeloma (2) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myelodysplastic Syndromes (1)
Hemic and Lymphatic Diseases (25) · Immune System Diseases (25) · Immunoproliferative Disorders (25) · Lymphatic Diseases (25) · Lymphoma (25) · Lymphoproliferative Disorders (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Hematologic Diseases (2)
Brentuximab Vedotin (5) · camrelizumab (5) · Decitabine (4) · Cyclophosphamide (3) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3) · Nivolumab (3) · Dacarbazine (2) · Doxorubicin (2) · Etoposide (2) · Procarbazine (2) · Rituximab (2) · Vinblastine (2) · Bendamustine Hydrochloride (1) · Bleomycin (1) · Busulfan (1)
Chinese PLA General Hospital (4) · Sheba Medical Center (2) · University College, London (2) · Beijing Children's Hospital (1) · Fudan University (1) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (1) · Han weidong (1) · IRCCS San Raffaele (1) · King Abdullah International Medical Research Center (1) · Medical University of Gdansk (1) · National Research Center for Hematology, Russia (1) · New York Medical College (1) · Ospedale Santa Croce-Carle Cuneo (1) · Peking University (1) · Peter MacCallum Cancer Centre, Australia (1)
China (9) · Italy (4) · Israel (3) · Australia (2) · Russia (2) · Spain (2) · United Kingdom (2) · France (1) · New Zealand (1) · Poland (1) · Saudi Arabia (1) · United States (1)
Arnon Nagler, MD (2) · Graham Collins (2) · Andrea Gallamini, Professor, PhD, MD (1) · Ayman Hejazi, MD (1) · Elena Parovichnikova,, MD,PhD (1) · Fabio FC Ciceri, MD (1) · Jan M Zaucha, Professor, PhD, MD (1) · Kirill Lepik, MD, PhD (1) · Massimo Federico, MD (1) · Michael Dickinson (1) · Mitchell Cairo, MD (1) · Natalia Mikhailova, MD (1) · Yanlong Duan (1)
PMID 40135712, PMID 29360414, PMID 31039052, PMID 32946355, PMID 33674274, PMID 33820822, PMID 34568066, PMID 38454451, PMID 39093981
2005 (1), 2017 (1), 2018 (1)